A immune response that as found to be similar among older and younger adults was produced by the under-trial vaccine candidate against Covi-19 being developed by the British pharmaceutical giant AstraZeneca.
The trial also fund that the potential adverse responses to the vaccine among the elderly were lower, said AstraZeneca, which is developing its potential Covid-19 vaccine in partnership with the University of Oxford.
There is apparently a greater chance and frequency of developing serious illness on contracting the coronavirus for older people, in addition to people of all ages with pre-existing medical conditions, compared to others, the World Health Organization has said.
The latest announcement by the British drug maker is likely to brighten the hops of the world getting a vaccine against the disease caused by the novel coronavirus even before the end of the current year or even very early next year.
“It is encouraging to see immunogenicity responses were similar between older and younger adults and that reactogenicity was lower in older adults, where the COVID-19 disease severity is higher,” an AstraZeneca spokesman to the media.
“The results further build the body of evidence for the safety and immunogenicity of AZD1222,” the spokesman said in reference to the technical name of the Oxford-AstraZeneca vaccine.
The news led to a 2 per cent jump in the shares of the drug maker.
There is currently a race going on among drug makers and research centers alike for developing and delivering the world with a safe and effective vaccine against Covid-19 which can help to bring an end to the coronavirus pandemic which has killed more than 1.16 million people throughout the world.
According to the WHO, there are dozens of Cvoid19 vaccine candidates around the world that are in clinical evaluation and some of the under-development vaccines are already undergoing late-stage trials among a large population of people prior to seeking formal approval form drug regulators of various countries.
It is widely believed that one of the frontrunners to secure regulatory approval is the vaccine candidate that is being jointly developed by the University of Oxford and AstraZeneca.
The vaccine from the drug maker would likely provide protection against contracting the coronavirus for about a year, AstraZeneca CEO Pascal Soirot has previously said.
(Adapted from CNBC.com)